title: Safety and clinical efficacy of golimumab in the treatment of arthritides.
abstract: Golimumab is a human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody that was recently approved for the treatment of patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. This review covers the published clinical trial data on the use of golimumab for the approved indications mentioned above with respect to efficacy and safety. The various ongoing trials for golimumab have yielded promising results in terms of efficacy and safety in methotrexate-naive and -resistant patients with rheumatoid arthritis, as well as in patients who were previously treated with other anti-TNF agents. In addition, the efficacy of golimumab in psoriatic arthritis and ankylosing spondylitis has also been demonstrated. The real safety information will be available only once the drug has been used in many more patients, who frequently have comorbid conditions.
authors.affiliation: New York University School of Medicine, NYU Hospital for Joint Diseases, New York, USA.
authors.forename: Ismail
authors.initials: I
authors.lastname: Simsek
authors.forename: Yusuf
authors.initials: Y
authors.lastname: Yazici